Utopia Foundation

Utopia Therapeutics is a biotechnology company dedicated to developing first-in-class immunotherapies and vaccines for chronic metabolic diseases, with a primary focus on obesity. The company's lead program, UT009, is a novel vaccine that targets lipid-associated antigens to modulate fat metabolism directly, offering a potential alternative to appetite-suppressing drugs like GLP-1 agonists without the associated muscle loss. Founded by a team of experienced scientists, including a co-discoverer of Lipitor, Utopia also utilizes a proprietary stem cell-based platform for regenerative medicine. The company is currently advancing its lead candidate through IND-enabling studies and toward Phase 1 clinical trials.